Skip to search formSkip to main contentSkip to account menu

HMR 3647

Known as: HMR-3647, HMR3647 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
BACKGROUND Malaria is on the increase due to emergence of parasite drug resistance and there is thus an urgent need for the… 
Highly Cited
2002
Highly Cited
2002
ABSTRACT The activity of a new ketolide, ABT-773, was compared to the activity of the ketolide telithromycin (HMR-3647) against… 
2001
2001
ABSTRACT The in vivo activity of telithromycin against erythromycin A- and penicillin G-resistant Streptococcus pneumoniae was… 
Review
2001
Review
2001
Recent semi-synthetic studies of erythromycin A culminated in the discovery of two ketolide drug candidates, HMR-3647 and ABT-773… 
Review
2001
Review
2001
The ketolide telithromycin (HMR-3647; Ketek), a derivative of clarithromycin, has been launched by Aventis Pharma (formerly… 
2000
2000
ABSTRACT The in vitro activity of telithromycin (HMR3647), a new ketolide, against Mycoplasma pneumoniae was determined by the… 
2000
2000
ABSTRACT The in vitro activities of HMR 3647 (telithromycin) and HMR 3004, two novel semisynthetic ketolides, were investigated… 
Highly Cited
1999
Highly Cited
1999
ABSTRACT HMR3647 is a semisynthetic representative of a new group of drugs, the ketolides, derived from erythromycin A. Since… 
1998
1998
ABSTRACT Ninety-four erythromycin-susceptible and 107 erythromycin-resistant enterococcal strains (MIC of ≥512 μg/ml) were…